12 results on '"Ghislaine Behar"'
Search Results
2. Supplementary Figure Legend from Single-Domain Antibody–Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells
- Author
-
Daniel Baty, Jean-Luc Teillaud, Patrick Chames, André Pèlegrin, Bruno Robert, Brigitte Kerfelec, Charlotte Boix, Ghislaine Behar, Martine Chartier, Corinne Pétiard, Amélie Cornillon, and Caroline Rozan
- Abstract
PDF file - 70K
- Published
- 2023
3. Supplementary Methods from Single-Domain Antibody–Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells
- Author
-
Daniel Baty, Jean-Luc Teillaud, Patrick Chames, André Pèlegrin, Bruno Robert, Brigitte Kerfelec, Charlotte Boix, Ghislaine Behar, Martine Chartier, Corinne Pétiard, Amélie Cornillon, and Caroline Rozan
- Abstract
PDF file - 120K
- Published
- 2023
4. Data from Single-Domain Antibody–Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells
- Author
-
Daniel Baty, Jean-Luc Teillaud, Patrick Chames, André Pèlegrin, Bruno Robert, Brigitte Kerfelec, Charlotte Boix, Ghislaine Behar, Martine Chartier, Corinne Pétiard, Amélie Cornillon, and Caroline Rozan
- Abstract
Antibody-dependent cell-mediated cytotoxicity, one of the most prominent modes of action of antitumor antibodies, suffers from important limitations due to the need for optimal interactions with Fcγ receptors. In this work, we report the design of a new bispecific antibody format, compact and linker-free, based on the use of llama single-domain antibodies that are capable of circumventing most of these limitations. This bispecific antibody format was created by fusing single-domain antibodies directed against the carcinoembryonic antigen and the activating FcγRIIIa receptor to human Cκ and CH1 immunoglobulin G1 domains, acting as a natural dimerization motif. In vitro and in vivo characterization of these Fab-like bispecific molecules revealed favorable features for further development as a therapeutic molecule. They are easy to produce in Escherichia coli, very stable, and elicit potent lysis of tumor cells by human natural killer cells at picomolar concentrations. Unlike conventional antibodies, they do not engage inhibitory FcγRIIb receptor, do not compete with serum immunoglobulins G for receptor binding, and their cytotoxic activity is independent of Fc glycosylation and FcγRIIIa polymorphism. As opposed to anti-CD3 bispecific antitumor antibodies, they do not engage regulatory T cells as these latter cells do not express FcγRIII. Studies in nonobese diabetic/severe combined immunodeficient gamma mice xenografted with carcinoembryonic antigen–positive tumor cells showed that Fab-like bispecific molecules in the presence of human peripheral blood mononuclear cells significantly slow down tumor growth. This new compact, linker-free bispecific antibody format offers a promising approach for optimizing antibody-based therapies. Mol Cancer Ther; 12(8); 1481–91. ©2013 AACR.
- Published
- 2023
5. A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy
- Author
-
Nidia Alvarez-Rueda, Caroline Bascoul-Mollevi, Françoise Roquet, Martine Pugnière, Isabelle Navarro-Teulon, Maha Zohra Ladjemi, Daniel Baty, André Pèlegrin, Ghislaine Behar, and Stéphanie Corgnac
- Subjects
Cell Survival ,Receptor, ErbB-2 ,medicine.drug_class ,Antibodies, Monoclonal, Humanized ,Monoclonal antibody ,Cancer Vaccines ,Mice ,Antigen ,Peptide Library ,Trastuzumab ,Cell Line, Tumor ,biology.domesticated_animal ,medicine ,Animals ,Humans ,skin and connective tissue diseases ,neoplasms ,Ovum ,Mice, Inbred BALB C ,General Veterinary ,General Immunology and Microbiology ,biology ,business.industry ,Immunogenicity ,Public Health, Environmental and Occupational Health ,Antibodies, Monoclonal ,Virology ,Lama glama ,Antibodies, Anti-Idiotypic ,Anti-idiotypic vaccine ,Infectious Diseases ,Single-domain antibody ,biology.protein ,Molecular Medicine ,Female ,Antibody ,business ,Camelids, New World ,medicine.drug - Abstract
HER2 over-expression in breast cancer correlates with reduced survival. Anti-idiotypic antibodies (Abs) that closely mimic HER2 could play a crucial role in the development of effective therapeutic vaccines. Here, we show that an anti-idiotypic single domain antibody (sdAb) 1HE isolated from a library generated from a Trastuzumab F(ab')(2)-immunized llama, closely mimics HER2. SdAb 1HE shows high affinity for Trastuzumab F(ab')(2), selectively inhibits HER2 binding to Trastuzumab F(ab')(2), and sera from sdAb 1HE-immunized BALB/c mice contain anti-HER2 antibodies that inhibit viability of HER2-positive cells. These results indicate that sdAb 1HE could be used as an anti-idiotype-based vaccine to boost immunity in patients bearing HER2-positive tumours.
- Published
- 2009
6. Characterization of the pasteurella multocida skp and firA genes
- Author
-
Henri Wroblewski, Rémi Houlgatte, Fabrice Manoha, Ulf Hellman, Ghislaine Behar, and Christian Delamarche
- Subjects
DNA, Bacterial ,Signal peptide ,Pasteurella multocida ,Operon ,Molecular Sequence Data ,lac operon ,Biology ,medicine.disease_cause ,Open Reading Frames ,Bacterial Proteins ,Escherichia coli ,Genetics ,medicine ,Amino Acid Sequence ,Cloning, Molecular ,ORFS ,Gene ,Peptide sequence ,Base Sequence ,Sequence Homology, Amino Acid ,Escherichia coli Proteins ,General Medicine ,Molecular biology ,DNA-Binding Proteins ,Open reading frame ,Genes, Bacterial ,Acyltransferases ,Molecular Chaperones - Abstract
A 2.9-kb fragment of the Pasteurella multocida (Pm) genome encoding proteins p25 (25 kDa) and p28 (28 kDa) has previously been cloned and expressed in Escherichia coli (Ec). In the present paper, the nucleotide (nt) sequence of a 1.8-kb subfragment encoding the two proteins is described. The cloned fragment contains three open reading frames (ORFs). ORF1 is incomplete. ORF2 is homologous to the skp gene of Ec. ORF3 overlaps ORF2 and is highly homologous to the firA gene of Ec. The skp and firA genes are part of an operon governing the first steps of lipid A synthesis. Comparing the nt sequence with the N-terminal sequences of p25 and p28 revealed that the two proteins are encoded by ORF2 (skp). The preprotein p28 is converted into p25 by cleavage of a 23-amino-acid leader peptide. Though it serologically cross-reacts with porin H of Pm, p25 is not related to known bacterial porins.
- Published
- 1995
7. Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen
- Author
-
Daniel Baty, Amélie Cornillon, Martine Pugnière, Ghislaine Behar, Isabelle Teulon, Anne Gruaz-Guyon, Françoise Roquet, Jean-Luc Teillaud, Patrick Chames, Faisal Al-Shoukr, André Pèlegrin, Unité de Biotechnologie, Biocatalyse et Biorégulation (U3B), Université de Nantes (UN)-Centre National de la Recherche Scientifique (CNRS), Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)
- Subjects
Male ,Phage display ,medicine.medical_treatment ,Molecular Sequence Data ,Mice, Nude ,Cross Reactions ,Immunofluorescence ,Biochemistry ,Antibodies ,Epitope ,Flow cytometry ,Epitopes ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Carcinoembryonic antigen ,Antigen ,Antibody Specificity ,Cell Line, Tumor ,Neoplasms ,medicine ,Animals ,Humans ,Amino Acid Sequence ,Molecular Biology ,030304 developmental biology ,0303 health sciences ,medicine.diagnostic_test ,biology ,Chemistry ,Cell Biology ,Immunotherapy ,Surface Plasmon Resonance ,Flow Cytometry ,Xenograft Model Antitumor Assays ,Molecular biology ,Carcinoembryonic Antigen ,3. Good health ,030220 oncology & carcinogenesis ,biology.protein ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Female ,Antibody ,[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology ,Camelids, New World ,Sequence Alignment - Abstract
International audience; Single-domain antibodies (sdAbs), which occur naturally in camelids, are endowed with many characteristics that make them attractive candidates as building blocks to create new antibody-related therapeutic molecules. In this study, we isolated from an immunized llama several high-affinity sdAbs directed against human carcinoembryonic antigen (CEA), a heavily glycosylated tumor-associated molecule expressed in a variety of cancers. These llama sdAbs bind a different epitope from those defined by current murine mAbs, as shown by binding competition experiments using immunofluorescence and surface plasmon resonance. Flow cytometry analysis shows that they bind strongly to CEA-positive tumor cells but show no cross-reaction toward nonspecific cross-reacting antigen, a highly CEA-related molecule expressed on human granulocytes. When injected into mice xenografted with a human CEA-positive tumor, up to 2% of the injected dose of one of these sdAbs was found in the tumor, despite rapid clearance of this 15 kDa protein, demonstrating its high potential as a targeting moiety. The single-domain nature of these new anti-CEA IgG fragments should facilitate the design of new molecules for immunotherapy or diagnosis of CEA-positive tumors.
- Published
- 2009
8. Isolation and characterization of anti-FcgRIII (CD16) llama single-domain antibodies that activate natural killer cells
- Author
-
Sophie Sibéril, Catherine Sautès-Fridman, Agnès Groulet, Martine Pugnière, Jean-Luc Teillaud, Patrick Chames, Daniel Baty, Ghislaine Behar, Charlotte Boix, Laboratoire d'Ingénierie et Dynamique des Systèmes membranaires [Marseille] (LIDSM/CNRS UPR9027), Centre National de la Recherche Scientifique (CNRS)-Institut de Biologie Structurale et Microbiologie [Marseille] (IBSM), Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de pharmacologie et innovation dans le diabète (CPID), Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), and Teillaud, Jean-Luc
- Subjects
[SDV.BIO]Life Sciences [q-bio]/Biotechnology ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,Antibody Affinity ,Bioengineering ,CD16 ,GPI-Linked Proteins ,Biochemistry ,Jurkat cells ,Epitope ,03 medical and health sciences ,Epitopes ,Interferon-gamma ,Jurkat Cells ,0302 clinical medicine ,Antigen ,Antigens, CD ,Antibodies, Bispecific ,Animals ,Humans ,Receptor ,Molecular Biology ,030304 developmental biology ,0303 health sciences ,biology ,Chemistry ,Receptors, IgG ,Transfection ,[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy ,[SDV.BIO] Life Sciences [q-bio]/Biotechnology ,Cell biology ,Killer Cells, Natural ,030220 oncology & carcinogenesis ,Immunology ,biology.protein ,Interleukin-2 ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Female ,[SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy ,Antibody ,Camelids, New World ,Biotechnology ,Conformational epitope - Abstract
FcgammaRIII (CD16) plays an important role in the anti-tumor effects of therapeutic antibodies. Bi-specific antibodies (bsAbs) targeting FcgammaRIII represent a powerful alternative to the recruitment of the receptor via the Fc fragment, but are not efficiently produced. Single-domain antibodies (sdAbs) endowed with many valuable structural features might help to bypass this problem. In the present work, we have isolated anti-FcgammaRIII sdAbs (C21 and C28) from a phage library generated from a llama immunized with FcgammaRIIIB extra-cellular domains. These sdAbs bind FcgammaRIIIA(+) NK cells and FcgammaRIIIB(+) polymorphonuclear cells, but not FcgammaRI(+) or FcgammaRII(+) cells, as detected by indirect immunofluorescence. Competition experiments showed that C21 and C28 sdAbs bind different FcgammaRIII epitopes, with C21 recognizing a linear and C28 a conformational epitope of the receptor. Surface plasmon resonance experiments showed that C21 and C28 sdAbs bind FcgammaRIII with a K(D) in the 10 and 80 nM range, respectively. Importantly, the engagement by both molecules of FcgammaRIIIA expressed by transfected Jurkat T cells or by NK cells derived from peripheral blood induced a strong IL-2 and IFN-gamma production, respectively. These anti-FcgammaRIII sdAbs represent versatile tools for generating bsAbs under various formats, able to recruit FcgammaRIII killer cells to target and destroy tumor cells.
- Published
- 2007
9. Generation of llama single-domain antibodies against methotrexate, a prototypical hapten
- Author
-
Virginie Ferré, Nidia Alvarez-Rueda, Stéphane Birklé, Françoise Roquet, Catherine Jacquot, Jacques Barbet, Jacques Aubry, Ghislaine Behar, Martine Pugnière, Daniel Baty, Louis Noël Gastinel, Centre hospitalier universitaire de Nantes (CHU Nantes), Institut de Recherche en Infectiologie de Montpellier (IRIM), and Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Phage display ,MESH: Amino Acid Sequence ,MESH: Base Sequence ,medicine.disease_cause ,01 natural sciences ,MESH: Recombinant Proteins ,MESH: Protein Structure, Tertiary ,MESH: Animals ,Peptide sequence ,0303 health sciences ,biology ,MESH: Escherichia coli ,Recombinant Proteins ,3. Good health ,MESH: Surface Plasmon Resonance ,Blot ,MESH: Methotrexate ,MESH: Haptens ,MESH: Camelids, New World ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Female ,Antibody ,Camelids, New World ,Hapten ,Molecular Sequence Data ,Immunology ,MESH: Sequence Alignment ,Antibodies ,03 medical and health sciences ,Peptide Library ,Escherichia coli ,medicine ,Animals ,Amino Acid Sequence ,Peptide library ,Molecular Biology ,030304 developmental biology ,MESH: Molecular Sequence Data ,Base Sequence ,MESH: Antibodies ,010401 analytical chemistry ,Surface Plasmon Resonance ,Molecular biology ,Protein Structure, Tertiary ,0104 chemical sciences ,Methotrexate ,Single-domain antibody ,biology.protein ,MESH: Peptide Library ,Haptens ,Sequence Alignment ,MESH: Female - Abstract
Single-domain antibodies specific to methotrexate (MTX) were obtained after immunization of one llama (Llama glama). Specific VHH domains (V-D-J-REGION) were selected by panning from an immune-llama library using phage display technology. The antibody fragments specific to MTX were purified from Escherichia coli (C41 strain) periplasm by immobilized metal affinity chromatography with an expression level of around 10mg/L. A single band around 16,000Da corresponding to VHH fragments was found after analysis by SDS-PAGE and Western blotting, while competition ELISA demonstrated selective binding to soluble MTX. Surface plasmon resonance (SPR) analysis showed that anti-MTX VHH domains had affinities in the nanomolar range (29-515nM) to MTX-serum albumin conjugates. The genes encoding anti-MTX VHH were found by IMGT/V-QUEST to be similar to the previously reported llama and human IGHV germline genes. The V-D and D-J junction rearrangements in the seven anti-MTX CDR3 sequences indicate that they were originated from three distinct progenitor B cells. Our results demonstrate that camelid single-domain antibodies are capable of high affinity binding to low molecular weight hydrosoluble haptens. Furthermore, these anti-MTX VHH give new insights on how the antigen binding repertoire of llama single-domain antibody can provide combining sites to haptens in the absence of a VL. This type of single-domain antibodies offers advantages compared to murine recombinant antibodies in terms of production rate and sequence similarity to the human IGHV3 subgroup genes.
- Published
- 2007
10. Artificial Affinity Proteins as Ligands of Immunoglobulins
- Author
-
Barbara Mouratou, Ghislaine Béhar, and Frédéric Pecorari
- Subjects
immunoglobulin ,Fc ,alternative scaffold protein ,Affibody ,Affitin ,DARPin ,monobody ,knottin ,CBM ,Microbiology ,QR1-502 - Abstract
A number of natural proteins are known to have affinity and specificity for immunoglobulins. Some of them are widely used as reagents for detection or capture applications, such as Protein G and Protein A. However, these natural proteins have a defined spectrum of recognition that may not fit specific needs. With the development of combinatorial protein engineering and selection techniques, it has become possible to design artificial affinity proteins with the desired properties. These proteins, termed alternative scaffold proteins, are most often chosen for their stability, ease of engineering and cost-efficient recombinant production in bacteria. In this review, we focus on alternative scaffold proteins for which immunoglobulin binders have been identified and characterized.
- Published
- 2015
- Full Text
- View/download PDF
11. Potent and specific inhibition of glycosidases by small artificial binding proteins (affitins).
- Author
-
Agustín Correa, Sabino Pacheco, Ariel E Mechaly, Gonzalo Obal, Ghislaine Béhar, Barbara Mouratou, Pablo Oppezzo, Pedro M Alzari, and Frédéric Pecorari
- Subjects
Medicine ,Science - Abstract
Glycosidases are associated with various human diseases. The development of efficient and specific inhibitors may provide powerful tools to modulate their activity. However, achieving high selectivity is a major challenge given that glycosidases with different functions can have similar enzymatic mechanisms and active-site architectures. As an alternative approach to small-chemical compounds, proteinaceous inhibitors might provide a better specificity by involving a larger surface area of interaction. We report here the design and characterization of proteinaceous inhibitors that specifically target endoglycosidases representative of the two major mechanistic classes; retaining and inverting glycosidases. These inhibitors consist of artificial affinity proteins, Affitins, selected against the thermophilic CelD from Clostridium thermocellum and lysozyme from hen egg. They were obtained from libraries of Sac7d variants, which involve either the randomization of a surface or the randomization of a surface and an artificially-extended loop. Glycosidase binders exhibited affinities in the nanomolar range with no cross-recognition, with efficient inhibition of lysozyme (Ki = 45 nM) and CelD (Ki = 95 and 111 nM), high expression yields in Escherichia coli, solubility, and thermal stabilities up to 81.1°C. The crystal structures of glycosidase-Affitin complexes validate our library designs. We observed that Affitins prevented substrate access by two modes of binding; covering or penetrating the catalytic site via the extended loop. In addition, Affitins formed salt-bridges with residues essential for enzymatic activity. These results lead us to propose the use of Affitins as versatile selective glycosidase inhibitors and, potentially, as enzymatic inhibitors in general.
- Published
- 2014
- Full Text
- View/download PDF
12. Isolation and characterization of anti-Fc{gamma}RIII (CD16) llama single-domain antibodies that activate natural killer cells.
- Author
-
Ghislaine Behar, Sophie Sibéril, Agnès Groulet, Patrick Chames, Martine Pugnière, Charlotte Boix, Catherine Sautès-Fridman, Jean-Luc Teillaud, and Daniel Baty
- Subjects
- *
KILLER cells , *IMMUNOFLUORESCENCE , *T cells , *TUMORS - Abstract
FcγRIII (CD16) plays an important role in the anti-tumor effects of therapeutic antibodies. Bi-specific antibodies (bsAbs) targeting FcγRIII represent a powerful alternative to the recruitment of the receptor via the Fc fragment, but are not efficiently produced. Single-domain antibodies (sdAbs) endowed with many valuable structural features might help to bypass this problem. In the present work, we have isolated anti-FcγRIII sdAbs (C21 and C28) from a phage library generated from a llama immunized with FcγRIIIB extra-cellular domains. These sdAbs bind FcγRIIIA NK cells and FcγRIIIB polymorphonuclear cells, but not FcγRI or FcγRII cells, as detected by indirect immunofluorescence. Competition experiments showed that C21 and C28 sdAbs bind different FcγRIII epitopes, with C21 recognizing a linear and C28 a conformational epitope of the receptor. Surface plasmon resonance experiments showed that C21 and C28 sdAbs bind FcγRIII with a KD in the 10 and 80 nM range, respectively. Importantly, the engagement by both molecules of FcγRIIIA expressed by transfected Jurkat T cells or by NK cells derived from peripheral blood induced a strong IL-2 and IFN-γ production, respectively. These anti-FcγRIII sdAbs represent versatile tools for generating bsAbs under various formats, able to recruit FcγRIII killer cells to target and destroy tumor cells. [ABSTRACT FROM AUTHOR]
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.